{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04501939: Phase 2 Interventional Active, not recruiting Chronic Lymphocytic Leukemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04541186: Phase 2 Interventional Completed Severe Hypertriglyceridemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03384745: Phase 2 Interventional Completed Psoriasis
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00027248: Phase 3 Interventional Completed Sepsis
(2000)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02822404: Not Applicable Interventional Completed Kidney Diseases
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03360461: Phase 2 Interventional Completed Colonic Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01678417: Phase 2 Interventional Unknown status Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:briquilimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03296696: Phase 1 Interventional Terminated Glioblastoma or Malignant Glioma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03237325: Phase 3 Interventional Completed Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
(2017)
Source URL:
Class:
PROTEIN
Dusquetide (also referred to by its research name SGX94) is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability. Preclinical data indicate that dusquetide is active in models of a wide range of therapeutic indications including severe side-effects of chemo- and/or radiation-therapy and life-threatening bacterial infections. Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified. A multi-center, double-blind, placebo-controlled, pivital Phase 3 clinical study in oral mucositis in head and neck cancer patients has been initiated.
